Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VYD2311 Phase 1 Study in Healthy Participants
NCT06523153Phase 1Active, not recruiting
- Sponsor
- Invivyd
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing VYD2311 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Aug 2024; status: active, not recruiting.
02
Drugs
VYD2311
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06523153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523153.